AC Immune SA
| NASDAQ: ACIU | Healthcare / Biotechnology / Switzerland |
| 3.51 | -0.0600 | -1.68% | Vol 84.77K | 1Y Perf 72.46% |
| Dec 7th, 2023 16:00 DELAYED |
| BID | 3.43 | ASK | 3.70 | ||
| Open | 3.55 | Previous Close | 3.57 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 10.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 203.99 | Finscreener Ranking | ★★★★ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 53.00 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 45.13 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 85.12 | Earnings Rating | Neutral | |
| Market Cap | 293.51M | Earnings Date | 3rd Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.17 | |
| Beta | 0.72 |
Today's Price Range 3.463.70 | 52W Range 1.683.83 | 5 Year PE Ratio Range -43.9019.70 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.24% | ||
| 1 Month | 17.00% | ||
| 3 Months | 6.69% | ||
| 6 Months | 58.11% | ||
| 1 Year | 72.46% | ||
| 3 Years | -30.77% | ||
| 5 Years | -68.52% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -9.71 | |||
ROE last 12 Months | -41.80 | |||
ROA (5Y Avg) | -7.88 | |||
ROA last 12 Months | -37.79 | |||
ROC (5Y Avg) | -14.01 | |||
ROC last 12 Months | -39.65 | |||
Return on invested Capital Q | -6.77 | |||
Return on invested Capital Y | -10.98 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.30 | ||||
| 0.89 | ||||
| 45.42 | ||||
| 8.90 | ||||
| -3.10 | ||||
| -0.95 | ||||
| 1.27 | ||||
| 2.43 | ||||
| 32.75M | ||||
| Forward PE | -5.86 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.60 | ||||
| 10.90 | ||||
| 0.01 | ||||
| 0.01 | ||||
| -137.50 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -1 848.90 | ||||
| -1 788.40 | ||||
| -320.00 | ||||
| -51.92 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.99M | ||||
| 0.05 | ||||
| -26.85 | ||||
| -12.76 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | 0.00 | -0.20 | - |
| Q02 2023 | -0.22 | -0.22 | 0.00 |
| Q01 2023 | -0.24 | -0.23 | 4.17 |
| Q04 2022 | -0.28 | -0.24 | 14.29 |
| Q03 2022 | -0.24 | -0.17 | 29.17 |
| Q02 2022 | -0.24 | -0.24 | 0.00 |
| Q01 2022 | -0.23 | -0.25 | -8.70 |
| Q04 2021 | - | -0.28 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | 0.01 | 104.17 | Positive |
| 12/2023 QR | -0.23 | 8.00 | Positive |
| 12/2023 FY | -0.68 | 4.23 | Positive |
| 12/2024 FY | -0.58 | 7.94 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 84.77K |
| Shares Outstanding | 83.62K |
| Shares Float | 33.36M |
| Trades Count | 920 |
| Dollar Volume | 304.51K |
| Avg. Volume | 58.11K |
| Avg. Weekly Volume | 73.31K |
| Avg. Monthly Volume | 51.40K |
| Avg. Quarterly Volume | 49.62K |
AC Immune SA (NASDAQ: ACIU) stock closed at 3.51 per share at the end of the most recent trading day (a -1.68% change compared to the prior day closing price) with a volume of 84.77K shares and market capitalization of 293.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 132 people. AC Immune SA CEO is Andrea Pfeifer.
The one-year performance of AC Immune SA stock is 72.46%, while year-to-date (YTD) performance is 72.06%. ACIU stock has a five-year performance of -68.52%. Its 52-week range is between 1.68 and 3.8299, which gives ACIU stock a 52-week price range ratio of 85.12%
AC Immune SA currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 0.89, a price-to-sale (PS) ratio of 45.42, a price to cashflow ratio of 8.90, a PEG ratio of -, a ROA of -37.79%, a ROC of -39.65% and a ROE of -41.80%. The company’s profit margin is -51.92%, its EBITDA margin is -1 788.40%, and its revenue ttm is $3.99 Million , which makes it $0.05 revenue per share.
Of the last four earnings reports from AC Immune SA, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AC Immune SA’s next earnings report date is -.
The consensus rating of Wall Street analysts for AC Immune SA is Strong Buy (1), with a target price of $10.67, which is +203.99% compared to the current price. The earnings rating for AC Immune SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AC Immune SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AC Immune SA has a Buy technical analysis rating based on Technical Indicators (ADX : 37.49, ATR14 : 0.22, CCI20 : 159.95, Chaikin Money Flow : 0.31, MACD : 0.16, Money Flow Index : 67.92, ROC : 10.03, RSI : 65.70, STOCH (14,3) : 77.73, STOCH RSI : 0.63, UO : 68.27, Williams %R : -22.27), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AC Immune SA in the last 12-months were:
AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
CEO: Andrea Pfeifer
Telephone: +41 216939121
Address: EPFL Innovation Park, Lausanne 1015, , CH
Number of employees: 132
